NASDAQ
22.95USD
+1.13 (+5.18%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.4B
P/E
—
EPS
—
Beta
-0.01
52W range
5.68-23.06
Day range
22.16–23.06
Open
22.16
Prev close
21.82
Volume
519.2K
Avg volume
938K
Dividend
0.00
IPO
2021-01-08
https://www.benzinga.com/trading-ideas/movers/26/08/61181387/cullinan-therapeutics-zipalertinib-combo-clears-key-phase-3-hurdle-as-first-line-lung-cancer-treatment-option-takes-shape · 8/13/2026+1.00
https://seekingalpha.com/article/4913841-cullinan-therapeutics-inc-cgem-discusses-promising-clinical-data-for-clnminus-978-and · 6/10/2026+0.80
https://seekingalpha.com/article/4896854-cullinan-therapeutics-cash-rich-with-a-major-2027-fda-catalyst · 4/30/2026+0.80
https://www.defenseworld.net/2026/03/28/cullinan-therapeutics-nasdaqcgem-versus-genprex-nasdaqgnpx-head-to-head-comparison.html · 3/28/2026+0.00
https://www.defenseworld.net/2026/03/14/cullinan-therapeutics-flags-2026-as-defining-year-at-leerink-tees-up-key-cln-978-cln-049-data.html · 3/14/2026
https://seekingalpha.com/article/4863651-cullinan-therapeutics-stock-cash-rich-biotech-multiple-value-drivers · 1/29/2026+1.00
https://www.defenseworld.net/2025/12/23/cullinan-therapeutics-nasdaqcgem-insider-jennifer-michaelson-sells-1345-shares.html · 12/23/2025-0.10
https://www.globenewswire.com/news-release/2025/12/08/3201707/0/en/Cullinan-Therapeutics-Showcases-Compelling-Clinical-Data-in-AML-for-CLN-049-Novel-FLT3xCD3-T-Cell-Engager-in-Oral-Presentation-at-the-67th-ASH-Meeting.html · 12/8/2025+1.00
https://www.globenewswire.com/news-release/2025/10/25/3174169/0/en/Cullinan-Therapeutics-Shares-Additional-Preclinical-B-Cell-Depletion-Data-for-CLN-978-Supporting-Clinical-Development-Across-Multiple-Autoimmune-Diseases-at-ACR-Convergence-2025.html · 10/25/2025+0.80
Cullinan Therapeutics, Inc. operates as a biopharmaceutical firm actively advancing its therapeutic candidates through clinical trials. This company is focused on developing innovative treatments primarily for cancer, including those that leverage the immune system (immuno-oncology). Its current roster of investigational drugs comprises CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. Patrick A. Baeuerle founded the organization on September 15, 2016, and it is presently headquartered in Cambridge, Massachusetts.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
